Antisense Oligonucleotide Inhibition of MicroRNA-494 Halts Atherosclerotic Plaque Progression and Promotes Plaque Stabilization by Ingen, E. van et al.
Original ArticleAntisense Oligonucleotide Inhibition of
MicroRNA-494 Halts Atherosclerotic Plaque
Progression and Promotes Plaque Stabilization
Eva van Ingen,1,2 Amanda C. Foks,3 Mara J. Kröner,3 Johan Kuiper,3 Paul H.A. Quax,1,2 Ilze Bot,3
and Anne Yaël Nossent1,2,4,5
1Department of Surgery, Leiden University Medical Center, 2300 RC, Leiden, the Netherlands; 2Einthoven Laboratory for Experimental Vascular Medicine, Leiden
University Medical Center, 2300 RC, Leiden, the Netherlands; 3Division BioTherapeutics, LACDR, Leiden University, 2333 CC, Leiden, the Netherlands; 4Department
of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria; 5Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, AustriaWe have previously shown that third-generation antisense
(3GA) inhibition of 14q32 microRNA (miRNA)-494 reduced
early development of atherosclerosis. However, patients at
risk of atherosclerotic complications generally present with
advanced and unstable lesions. Here, we administered
3GAs against 14q32 miRNA-494 (3GA-494), miRNA-
329 (3GA-329), or a control (3GA-ctrl) to mice with
advanced atherosclerosis. Atherosclerotic plaque formation
in LDLr/ mice was induced by a 10-week high-fat diet
and simultaneous carotid artery collar placement. Parallel
to 3GA-treatment, hyperlipidemia was normalized by a
diet switch to regular chow for an additional 5 weeks. We
show that, even though plasma cholesterol levels were
normalized after diet switch, carotid artery plaque progres-
sion continued in 3GA-ctrl mice. However, treatment with
3GA-494 and, in part, 3GA-329 halted plaque progression.
Furthermore, in the aortic root, intra-plaque collagen con-
tent was increased in 3GA-494 mice, accompanied by a
reduction in the intra-plaque macrophage content. Pro-
atherogenic cells in the circulation, including inflammatory
Ly6Chi monocytes, neutrophils, and blood platelets, were
decreased upon miRNA-329 and miRNA-494 inhibition.
Taken together, treatment with 3GA-494, and in part with
3GA-329, halts atherosclerotic plaque progression and pro-
motes stabilization of advanced lesions, which is highly rele-
vant for human atherosclerosis.Received 14 June 2019; accepted 24 September 2019;
https://doi.org/10.1016/j.omtn.2019.09.021.
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Atherosclerosis is a chronic inflammatory disease characterized by
progressive plaque buildup in the arterial wall. Most plaques that
develop during one’s life remain clinically silent. However, lesion pro-
gression and disruption of a vulnerable plaque may result in a cardio-
vascular event, such as an ischemic stroke or myocardial infarction.1
Surgical interventions to prevent, for example, ischemic stroke are ca-
rotid endarterectomy or stenting, but due to the perioperative risks,
these are only performed when a plaque causes a stenosis of the ca-
rotid artery of more than 70% or when the plaque is symptomatic,
i.e., causing transient ischemic attacks (TIAs).2638 Molecular Therapy: Nucleic Acids Vol. 18 December 2019 ª 2019
This is an open access article under the CC BY-NC-ND license (httpAn established therapeutic strategy is plasma lipid lowering by sta-
tins. Lipid-lowering strategies have been shown to contribute to
increased plaque stability and reduce the risk of (recurrent) cardio-
vascular events, including myocardial infarction.3–5 Independent of
lipid lowering, targeting inflammation is also important in
reducing the incidence of recurrent cardiovascular events, as was
demonstrated in the canakinumab anti-inflammatory thrombosis
outcome study (CANTOS) trial.6 Although current therapeutic
strategies contribute to reducing the risk of recurrent cardiovascu-
lar events, a clinical need remains for novel noninvasive therapies
targeting multiple aspects of atherosclerosis and improving clinical
outcome. Therapeutic strategies increasing stabilization of vulner-
able plaques, alone or complemented by existing lipid-lowering
treatments, would be of great clinical value in reducing the risk
of thrombotic events in the carotid, coronary, and peripheral
arteries.
MicroRNAs (miRNAs) are post-transcriptional negative regulators of
gene expression. Because of their ability to fine-tune expression of
multiple target genes, miRNAs are promising drug targets for com-
plex diseases, including atherosclerosis.7 Several studies have focused
on the therapeutic potential of miRNA-modulation in atheroscle-
rosis. For example, the miRNA-33 family, including miRNA-33a
and miRNA-33b, regulates cholesterol metabolism by targeting
cholesterol transporter ABCA1. Inhibition of miRNA-33 resulted in
decreased very low-density lipoprotein (VLDL), whereas high-den-
sity lipoprotein (HDL) was increased in the plasma.8–10 More
recently, it was shown that miRNA-33 inhibition also promotes
cholesterol efflux from arterial macrophages and thereby directly
regulates atherosclerotic plaque formation.11 Inflammation in athero-
sclerosis was reduced via miRNA-155 inhibition. miRNA-155 is pre-
dominantly expressed in pro-inflammatory macrophages. InhibitionThe Authors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Total Cholesterol Levels and Bodyweight
Levels of LDLr–/– Mice Treated with 3GA-ctrl, 3GA-
494, or 3GA-329
Mice received 3GA treatment immediately after (baseline)
and 2 and 4 weeks after diet replacement from high-fat
high cholesterol to regular chow. All mice were sacrificed
at week 5. (A) Total cholesterol (TC) levels in mg/dL
measured in the serum of 3GA-ctrl-, 3GA-494-, and
3GA-329-treated mice, quantified by using enzymatic
procedures, at baseline and up to 5 weeks after diet
replacement. (B) Zoomed-in graph of TC at weeks 3 and
5. (C) Bodyweight levels in g after diet replacement. A two-tailed Student’s t test was performed to compare single treatment to the 3GA-ctrl group at each time point. *p <
0.05 compared to 3GA-ctrl. 3GA-ctrl (N = 10), 3GA-494 (N = 10), and 3GA-329 (N = 8). Data are represented as mean ± SEM.
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fewer lipid-laden macrophages via increasing expression of its target
BCL6, which attenuates pro-inflammatory nuclear factor kB (NF-kB)
signaling.12 Furthermore, plaque stability was shown to increase upon
overexpressing miRNA-210. miRNA-210 inhibits adenomatous
polyposis coli (APC) expression in smooth muscle cells (SMCs)
and thereby enhances intra-plaque SMC survival and, thus, intra-
plaque collagen synthesis.13 However, as one miRNA can have mul-
tiple target genes, single miRNAs also have the potential to
target all aspects of atherosclerosis at once. For example, inhibition
of miRNAs transcribed from the 14q32 cluster (12F1 in mice) tar-
geted multiple aspects in atherosclerosis, including lipid hemostasis,
inflammation, and concomitant plaque development, as we have
shown previously.14
The 14q32 cluster is the largest known miRNA gene cluster in hu-
mans and contains more than 50 miRNA genes. We have evaluated
the therapeutic inhibition of 14q32 miRNAs in different vascular re-
modeling processes.14–17 In two different murine models of vascular
remodeling, one for intimal hyperplasia and one for accelerated
atherosclerosis, we showed that inhibition of 14q32 miRNAs reduced
initial lesion development, increased plaque stability, and decreased
plasma cholesterol levels.14,16 Importantly, inhibition of 14q32
miRNAs reduced macrophage influx in the intima in the intimal hy-
perplasia model.16 These studies, however, focused on the effects of
14q32 miRNA inhibition in initial lesion development,14 where
most patients present in the clinic with advanced, symptomatic
atherosclerotic lesions.
In the current study, we therefore aimed to investigate the effects of
14q32 miRNA inhibition on advanced lesions. We used third-gener-
ation antisense (3GA) to inhibit two different 14q32 miRNAs,
miRNA-494 andmiRNA-329. Parallel to 3GA treatment, we included
a diet switch from high-fat high-cholesterol to regular chow to
normalize hyperlipidemia, in order to closely mimic routine lipid-
lowering treatment.
First, we show that inhibition of 14q32miRNAs, particularly miRNA-
494, halted atherosclerotic plaque progression and increased plaque
stability in mice with advanced atherosclerotic lesions. Second, we
show that plasma cholesterol levels show a modest but further reduc-tion after miRNA-494 and miRNA-329 inhibition. Third, we show
that pro-atherogenic cells in the circulation, including inflammatory
Ly6Chi monocytes, neutrophils, and platelets, were decreased upon
miRNA-329 and miRNA-494 inhibition, which is highly relevant in
further reducing the risk of atherosclerotic complications.
RESULTS
3GA-494 and 3GA-329 Treatment Reduces Plasma Cholesterol
Levels and Body Weight
The timeline of the study is shown in Figure S1. Plasma cholesterol
levels showed a clear decrease in all groups after diet replacement
(Figure 1A). Both 3GA-494- and -329-treated groups showed a
further reduction in total plasma cholesterol levels compared to
the 3GA-control (3GA-ctrl) 5 weeks after diet switch (3GA-494,
155 ± 6 mg/dL; 3GA-329, 168 ± 11 mg/dL; versus 3GA-ctrl,
214 ± 13 mg/dL, p < 0.05; Figure 1B). Similar to as shown previ-
ously,18 body weight did not significantly differ after diet switch in
the 3GA-ctrl group as compared to baseline but showed a reduction
in 3GA-494- or 3GA-329-treated mice compared to 3GA-ctrl (Fig-
ure 1C). Subsequently, all groups increased in body weight during
the remainder of the study, independent of the treatment, but body
weight levels of 3GA-494- and 3GA-329-treated mice remained
decreased compared to 3GA-ctrl. The size of the spleen was increased
in all of the 3GA-494-treated mice and in half of the 3GA-329-treated
mice, as is further described below. All other organs appeared normal,
and mice did not show any pathological changes.
3GA-494 Treatment Halts Plaque Progression in the Carotid
Artery
In the carotid arteries, miRNA-494 and miRNA-329 expression were
inhibited in both 3GA-494 and 3GA-329, respectively, compared to
3GA-ctrl (Figure 2A). miRNA-494 and miRNA-329 target gene
expression levels (miRNA-494—IL33, TIMP3, and TLR4; miRNA-
329—VEGFA, Mef2A, and TLR4), however, were not significantly
different compared to the control 1 week after final 3GA injections
(Figures S2A and S2B). 3GA-ctrl-treated mice showed increased ca-
rotid artery average plaque size compared to baseline, indicating
continued atherogenesis, even after lowering plasma cholesterol
levels by diet replacement (baseline, 18 ± 4  103 mm2, versus
3GA-ctrl, 32 ± 10  103 mm2; Figures 2B and 2D). At the site of
maximal stenosis, plaque size was increased in 3GA-ctrl comparedMolecular Therapy: Nucleic Acids Vol. 18 December 2019 639
Figure 2. Inhibition of miRNA-494 and miRNA-329 in
Atherosclerotic Lesions in the Carotid Artery
(A) Levels of miRNA-494 (N = 3) andmiRNA-329 (N = 3) in
carotid arteries of LDLr/ mice 1 week after the final in-
jection of 3GA-494 and 3GA-329, respectively, normal-
ized to miRNA-494 and miRNA-329 expression in mice
treated with 3GA-ctrl (100%; N = 3). miRNA-191 was
used as a reference gene. (B) Average plaque size
(calculated as the size average of plaque sections taken
100 mm apart) in the carotid arteries of baseline (N = 7),
3GA-ctrl (N = 6), 3GA-494 (N = 8), and 3GA-329 mice
(N = 6) and (C) plaque size at the site of maximal stenosis
in mm2 in the carotid arteries of baseline (N = 7), 3GA-ctrl
(N = 6), 3GA-494 (N = 8), and 3GA-329 mice (N = 6). (D)
Representative images of all groups. Scale bar, 100 mm. A
two-tailed Student’s t test was performed to compare
single treatment to the 3GA-ctrl group. A Grubbs’ test
was used to identify significant outliers (a < 0.05). *p <
0.05 compared to 3GA-ctrl. Data are represented as
mean ± SEM.
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103 mm2; Figure 2C). In 3GA-494 mice, carotid artery plaque size was
significantly decreased compared to 3GA-ctrl. In fact, 3GA-494 mice
had similar plaque sizes to baseline mice in both average plaque sizes
(baseline, 18 ± 4  103 mm2; 3GA-ctrl, 32 ± 10  103 mm2, versus
3GA-494, 13 ± 3  103 mm2, p < 0.05; Figures 2B and 2D) and at
the site of maximal stenosis (baseline, 30 ± 8  103 mm2; 3GA-ctrl,
56 ± 16 103 mm2; versus 3GA-494, 23 ± 7 103 mm2, p < 0.05; Fig-
ure 2C). 3GA-329-treated mice showed a trend toward a smaller
average plaque size and at the site of maximal stenosis (average,
3GA-329, 15 ± 1  103 mm2, p = 0.09; maximal stenosis, 3GA-329,
21 ± 3  103 mm2, p = 0.1; Figures 2B–2D). Due to the small size,
most plaques showed a fatty streak phenotype rather than an
advanced atherosclerotic plaque phenotype. Advanced atheroscle-
rotic plaque features, such as a fibrous cap and necrotic core, were
lacking in most plaques, and therefore, we were unable to quantify
and compare this among the groups.
Inhibition of miRNA-494 Increases Plaque Stability in Advanced
Plaques
In the aortic root, plaque size and necrotic core size did not differ
between groups (Figures 3A and 3B). Other markers for plaque sta-
bility, however, were increased after miRNA-494 and, in part,
miRNA-329 inhibition (Figures 3C–3E). Intra-plaque collagen con-
tent was strongly increased in 3GA-494 mice compared to the con-
trol (3GA-ctrl, 37% ± 3%, versus 3GA-494 55% ± 3%, p < 0.0005;
Figure 3C). Treatment with 3GA-329 resulted in four mice in
increased collagen content, whereas the other four showed similar
collagen content as baseline mice (baseline, 15% ± 2%, versus
3GA-329, 34% ± 9%; Figure 3C). SMCs are the main source of
collagen synthesis in atherosclerotic plaques, but the SMC content
was similar in all groups (baseline, 12% ± 1%; 3GA-ctrl, 14% ±
1%; 3GA-494, 11% ± 1%; 3GA-329, 13% ± 1%; Figure 3D). Relative
intra-plaque macrophage area was reduced upon diet switch from640 Molecular Therapy: Nucleic Acids Vol. 18 December 2019diet with high-fat high-cholesterol to regular chow (baseline,
22% ± 2%, versus 3GA-ctrl, 17% ± 2%; Figure 3E). In 3GA-494
mice, a further reduction in intra-plaque macrophage content was
shown (3GA-ctrl, 17% ± 2%, versus 3GA-494, 12% ± 1%, p <
0.05; Figure 3E), which is another marker of increased plaque stabil-
ity. For the 3GA-329 treated mice, the relative macrophage area re-
mained similar to control levels (3GA-329, 17% ± 2%; Figure 3E).
Numbers of intra-plaque neutrophils were very small and not
different among the groups (data not shown). Plaque necrotic
core sizes were not significantly different between groups as well
(Figure 3E).
Blood, Spleen, and Lymph Node Analyses of LDLr–/– Mice
Treated with 3GA-494, 3GA-329, or 3GA-ctrl
Blood analysis by Sysmex and flow cytometry revealed altered
numbers of circulating cells upon 3GA-494 and 3GA-329 treatment
compared to 3GA-ctrl (Figure 4 and Figure S3). White blood cells
(WBCs) remained similar after miRNA-494 inhibition but were
decreased after miRNA-329 inhibition (Figure 4A). Myeloid cells,
as defined by CD11b+ and CD11c+CD11b+, were elevated in 3GA-
494 mice, whereas CD11b+ cells were decreased in 3GA-329 mice
(Figures S3A and S3B). More specifically, we observed that neutro-
phils (Ly6C+Ly6Gint), which are part of the myeloid compartment
of WBCs, were decreased after miRNA-494 and miRNA-329 inhibi-
tion (Figures 4B and 4C). The total monocyte count, also part of the
myeloid compartment of WBCs, was not significantly altered,
although we did observe differences in the pro-inflammatory subset
(Ly6C+Ly6G) quantified by fluorescence-activated cell sorting
(FACS) analysis (Figures 4D and 4E).
Although total amounts of lymphocytes were similar, CD19+ B cells
were reduced in 3GA-494 mice, and CD4+ and CD8+ T cells were
slightly increased in 3GA-329 mice (Figure 4F and Figures S3C–
S3E). Furthermore, miRNA-494 inhibition decreased red blood cell
Figure 3. 3GA-494 Treatment Increased Plaque Stability in
Aortic Root Plaques
(A) Plaque size in mm2 of aortic root plaques, calculated from at
least five 10-mm-thick sections of the three-valve area. (B)
Necrotic core area, defined as an acellular area, measured in the
lesions stained with Masson’s trichrome; (C) collagen content,
stained with Massons’s trichrome; (D) SMC content, stained with
an antibody against a-smooth muscle actin (a-SMA); and (E)
macrophage content, stained with anti-monocyte-macrophage
(Moma)-2 antibody. Amount of staining is shown as a percentage
of total plaque area quantified in baseline (N = 10), 3GA-ctrl (N =
10), 3GA-494 (N = 10), and 3GA-329 (N = 8). (C–E) Scale bar,
250 mm. A two-tailed Student’s t test was performed to compare
single treatment to the 3GA-ctrl group. A Grubbs’ test was used
to identify significant outliers (a < 0.05). *p < 0.05, ***p < 0.0005
compared to 3GA-ctrl. Data are represented as mean ± SEM.
www.moleculartherapy.organd, in particular, strongly reduced platelet count (Figures 4G and
4H). In the 3GA-329-treated mice, three mice showed reduced
platelet counts, whereas platelet counts were normal in the remaining
mice (Figure 4H).
Percentages of CD4+ and CD8+ T cells in the spleen were decreased
in 3GA-494-treated mice and showed a trend toward a reduction
in 3GA-329-treated mice (Figures S3F and S3G). However, since
the spleens were enlarged due to proliferation of other cell types, as
discussed below, the absolute numbers of CD4+ and CD8+ T cells
may be similar among all groups. CD4+ and CD8+ T cells in the drain-
ing lymph nodes were not different among all groups (Figures S3H
and S3I).MolecularSplenic Megakaryocyte Retention
As mentioned above, all 3GA-494 mice and half of the
3GA-329 mice showed splenomegaly compared to
3GA-ctrl and baseline mice (Figures 5A and 5B). Stain-
ing forVonWillebrand factor (VWF) revealed strongly
elevated numbers of megakaryocytes in the enlarged
spleens of 3GA-494 mice compared to 3GA-ctrl, indi-
cating increased megakaryopoiesis (Figures 5A and
5C). In 3GA-329 mice, only the mice with low platelet
counts showed splenomegaly, accompanied by strongly
elevated megakaryocyte numbers (Figure 5B). Despite
the administration of a miRNA-494 inhibitor, splenic
expression ofmiRNA-494was upregulated 1week after
the final 3GA injection (Figure 5C). Increased expres-
sion of megakaryocyte/platelet markers, i.e., glycopro-
tein Ib platelet subunit alpha (GPIba) and subunit
beta (GpIbb), both part of the platelet receptor complex
for VWF, and integrin subunit beta 3 (Itgb3), in the
spleen of 3GA-494 mice confirmed indeed increased
megakaryopoiesis (Figures 5D–5F). megakaryocytes
and erythrocytes derive from a bipotent erythrocytic-
megakaryocyte progenitor. Transcription factors
involved in commitment of erythrocytic-megakaryo-cyte progenitor cells toward megakaryocyte progenitors and platelet
production were also increased upon 3GA-494 treatment (Figures
5G–5I).19 Expression of transcription factors involved in hematopoietic
stem cell (HSC) proliferation and differentiation, which are putative
targets of miRNA-494 and conserved in both human and mouse, as
was predicted by http://www.targetscan.org (release 7.2), was similar
in both 3GA-494- and 3GA-ctrl-treated mice (Figure S2C).20–23 In
the spleen of 3GA-329 mice, no significant differences in megakaryo-
cyte/platelet markers or transcription factor expression was shown
compared to 3GA-ctrl mice (Figures 5D–5I).
A previous study showed that in primary myelofibrosis, overexpres-
sion of miRNA-494 in HSCs promotes megakaryopoiesis viaTherapy: Nucleic Acids Vol. 18 December 2019 641
Figure 4. Blood Analysis of Mice Treated with 3GA-494, 3GA-329, or 3GA-ctrl 1 Week after Final Injection
(A–H) Amount of circulating (A) white blood cells (WBC; 106/L), (B) neutrophils (106/L), and (C) neutrophil marker lymphocyte antigen 6 complex, locus G6D (Ly6G+) lymphocyte
antigen 6 complex, locus C1 (Ly6C)int cells defined as a percentagewithin CD11b+ cells, (D) monocytes (106/L), and (E) inflammatory subset of monocyte Ly6G-Ly6Chi cells as a
percentagewithinCD11b+cells, (F) lymphocytes (106/L), (G) redbloodcells (RBC;1012/L), and (H)platelets (109/L). (A,C, andE–H)Bloodcell analysisonwholebloodquantifiedby
Sysmex. (C and E) Fluorescence-activated cell sorting analysis (FACS) analysis performed on the blood of 3GA-ctrl, 3GA-494, and 3GA-329 mice after red blood cells were
removed using lysis buffer. A two-tailed Student’s t test was performed to compare single treatment to the 3GA-ctrl group. A Grubbs’ test was used to identify significant outliers
(a < 0.05). *p < 0.05, **p < 0.005, ****p < 0.0001 compared to 3GA-ctrl. 3GA-ctrl (N = 10), 3GA-494 (N = 10), and 3GA-329 (N = 8). Data are represented as mean ± SEM.
Molecular Therapy: Nucleic Acidsdownregulation of suppressor of cytokine signaling 6 (SOCS6).24 We
quantified SOCS6 expression in the spleen. However, SOCS6 expres-
sion showed a trend toward upregulation compared to 3GA-ctrl
instead of downregulation (Figure S2D). As the bone marrow is also
a source of megakaryopoiesis, we stimulated freshly isolated murine
bone marrow cells with either 3GA-ctrl or 3GA-494. Although the
miRNA-494 expression was downregulated in bonemarrow cells after
3GA-494 treatment, we did not observe differences in SOCS6 expres-
sion nor in expression of transcription factors for megakaryocyte
commitment andGPIba andGpIbb expression (Figures S2E and S2F).
Increased Hepatic Platelet Markers
Platelets can be cleared by hepatocytes and liver macrophages
(Kuppfer cells).25 Expression of miRNA-494 in the liver was similar642 Molecular Therapy: Nucleic Acids Vol. 18 December 2019in both 3GA-494 and 3GA-ctrl mice (Figure 6A). miRNA-329 was
not expressed at all in the liver of either 3GA-329 or 3GA-ctrl
mice (data not shown). Expression levels of platelet markers quanti-
fied by qPCR were upregulated in the liver of 3GA-494-treated mice,
suggesting increased platelet clearance compared to 3GA-ctrl (Fig-
ures 6B–6D). In 3GA-329 mice, only the mice with low platelet
counts showed increased expression of platelet markers in the liver
(Figures 6B–6D).
Increased Expression of Platelet Receptors upon 3GA-494
Treatment
We further investigated whether 3GA-494 treatment could lead to
miRNA-494 inhibition in anucleate platelets. Compared to 3GA-
ctrl, mature miRNA-494 expression was first downregulated after
(legend on next page)
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Figure 6. Increased Platelet Receptor Expression in
the Liver of 3GA-494 Mice
(A) miRNA-494 expression in the liver of mice treated with
3GA-494 (N=9)or 3GA-ctrl (N=10), relative tomiRNA-191.
(B) Relative expression of three different platelet/megakar-
yocyte markers quantified by qPCR in the liver of 3GA-ctrl
(N = 10), 3GA-494 (N = 10), and 3GA-329 (N = 8) mice;
glycoprotein Ib platelet subunit alpha (GP1b-a), (C) beta
chain (GP1b-b), and (D) integrin subunit beta 3 (Itgb3)
normalized to Gapdh and Hprt. (B–D) A Mann-Whitney U
testwasperformed tocomparesingle treatment to the3GA-
ctrl group. A Grubbs’ test was used to identify significant
outliers (a < 0.05). *p < 0.05, ****p < 0.0001, compared to
3GA-ctrl. Data are represented as mean ± SEM.
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ure 7A). As platelets have no transcription, upregulation of miRNA-
494 was accompanied by depletion of the primary miRNA-494
transcript, pri-miRNA-494, indicating rapid processing of the pri-
miRNA-494 upon miRNA-494 downregulation (Figure 7B). Changes
in the intermediate precursor miRNA-494, pre-miRNA-494, were
less pronounced (Figure 7C).
Genes that we initially tested as housekeeping genes, including
GAPDH, U6, and YWHAE, appeared to be unstable in 3GA-treated
platelets (Figures S4B–S4D).26 Pre-ITGb3 showed stable expression
and was, therefore, used as a housekeeping gene (Figure S4A). Pro-
survival genes BCL2 and MCL1 are putative targets of miRNA-494,
as was predicted by http://www.targetscan.org (release 7.2). Since
miRNA-494 was upregulated in platelets, we checked whether
BCL2 and MCL1 were downregulated, leading to more apoptosis
and subsequently to more clearance. MCL1 appeared downregulated
in 3GA-494, but BCL2 did not (Figures S4E and S4F).
Next, we quantified expression of platelet GPIBa and integrin subunit
ITGb3, both part of platelet receptors involved in platelet activation,
and found upregulation after 4 h of 3GA-494 treatment compared to
3GA-ctrl (Figures 7D–7F). Since splicing occurs upon platelet activa-
tion, we measured pre-mRNA levels of MCL1, GAPDH, and GPIB-
a.27,28 Pre-mRNA levels were declined in 3GA-494-treated platelets
compared to 3GA-ctrl, indicating increased splicing and hence
increased platelet activation in 3GA-494-treated platelets (Figures
S4G–S4I).
Time points from 8 h on were excluded, since all platelets, indepen-
dent of their treatment, were hyper-activated in culture.Figure 5. Megakaryocyte Accumulation in the Spleen upon 3GA-494 and 3GA-
(A) Representative images of splenomegaly in 3GA-494-treated mice with megakar
an antibody against VWF. Scale bar, 500 mm. Zoomed-in image; scale bar, 50 mm. (B) W
(N = 8). (C) Number of megakaryocytes per mm2 spleen. (D) miRNA-494 expression in th
different platelet/megakaryocyte markers quantified by qPCR in the spleen; glycoprotein
beta 3 (Itgb3) normalized to Gapdh and Hprt. (H–J) Transcription factors involved in me
bHLH transcription factor 1, erythroid differentiation factor (Tal1), and (J) nuclear fac
single treatment to the 3GA-ctrl group. AGrubbs’ test was used to identify significant out
(N = 10), 3GA-494 (N = 10), and 3GA-329 (N = 8). Data are represented as mean ± SE
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In this study, we first show that inhibition of 14q32 miRNAs, partic-
ularly miRNA-494, in mice with advanced atherosclerotic lesions
halted carotid atherosclerotic plaque progression and promoted pla-
que stability in the aortic root of LDLr/ mice. Second, plasma
cholesterol levels were lowered further by 14q32 miRNA inhibition
than by diet switch alone. Third, pro-atherogenic cells in the circula-
tion, including pro-inflammatory monocytes (Ly6Chi), neutrophils,
and platelets were decreased after miRNA-329 and miRNA-494
inhibition.
Even though plasma cholesterol was lowered by diet switch, plaques
in the carotid artery continued to grow in 3GA-ctrl mice. With 3GA-
494 treatment and, in part, 3GA-329 treatment, we managed to halt
plaque progression in the carotid artery. Although we combined
3GA treatment with plasma lipid lowering, plaque sizes from 3GA-
494- and 3GA-329-treated mice were not significantly reduced
compared to baseline, indicating that plaque regression did not occur
in this setup. Unlike for the carotid artery lesions, neither 3GA-494
treatment nor 3GA-329 treatment resulted in reduced plaque sizes
in the aortic root compared to 3GA-ctrl treatment. We have previ-
ously established that the expression of 14q32 miRNAs differs be-
tween sites of lesion development in mice,14 and more recently, we
demonstrated that expression of 14q32 miRNAs, including
miRNA-494 and miRNA-329 and their targets, varies widely across
the human vasculature as well.29 Differences in response to miRNA
inhibition in carotid artery plaques and aortic root plaques are, there-
fore, likely caused by differences in local miRNA and target gene
expression. Although plaque size was not affected in the aortic root,
plaque stability was clearly affected and increased after miRNA-494
inhibition, which is particularly relevant in reducing the risk of329 Treatment
yocyte accumulation compared to 3GA-ctrl. Megakaryocytes were stained with
eight in g of the spleens of 3GA-ctrl (N = 10), 3GA-494 (N = 10), and 3GA-329 mice
e spleen of 3GA-ctrl and 3GA-494mice, relative to miRNA-191 expression. (E) Three
Ib platelet subunit alpha (GP1b-a), (F) beta (GP1b-b) chain, and (G) integrin subunit
gakaryocyte differentiation in the spleen. (H) Gata binding protein 1 (Gata1), (I) TAL
tor, erythroid 2 (Nfe2). A two-tailed Student’s t test was performed to compare
liers (a < 0.05). *p < 0.05, **p < 0.005, ****p < 0.0001 compared to 3GA-ctrl. 3GA-ctrl
M.
Figure 7. Upregulation of miRNA-494 Expression
following 3GA-494 Treatment Led to Hyper-
Activation of Platelets
Human platelets were incubated up to 4 h in PAS-III
buffer with 30%–35% plasma with either 3GA-494 or
3GA-ctrl (in triplos). Platelets were kept in an incubator at
22C with 5% CO2 at continuously swirling. (A) Mature
miRNA-494 expression, relative to miRNA-126. (B) Pri-
miRNA-494 and (C) pre-miRNA-494 relative to pre-in-
tegrin subunit beta 3 (Itgb3) expression. (D) Expression
levels of platelet receptors glycoprotein Ib platelet subunit
alpha (GP1B-a), (E) beta chain (GP1B-b), and (F) ITGb3,
relative to pre-ITGb3 expression. All expression levels
were normalized to 3GA-ctrl (100%). Data are repre-
sented as mean ± SEM.
www.moleculartherapy.orgcardiovascular events. These results indicate that 3GA-494 treatment
would be relevant for treating different types of plaques, developing at
different sites in the vasculature.
Collagen provides structural support in the fibrotic cap and in
our study, particularly miRNA-494 inhibition increased intra-
plaque collagen content in advanced lesions. Collagen is synthe-
sized by SMCs, however, we have previously shown that
miRNA-494 does not affect collagen synthesis.14 Furthermore,
even though miRNA-494 does affect proliferation of myofibro-
blasts,15 neither miRNA-494 nor miRNA-329 inhibition affected
the intra-plaque SMC content, which indicates that another mech-
anism caused the enhanced collagen deposition. We previously
validated tissue inhibitor of metalloproteinases 3 (TIMP3) as a
target of miRNA-494.14 TIMP3 inhibits collagen degradation by
matrix metalloproteinases (MMPs) and, therefore, more TIMP3
expression likely contributed to the observed increase in collagen
content. Since macrophages produce MMPs, the reduced intra-
plaque macrophage content may also have contributed to the
increased collagen content in the plaques. Lipid-lowering strategies
have been described to contribute to fewer intra-plaque macro-
phages.30 Fewer intra-plaque macrophages are associated with a
more stable plaque phenotype. In our study, macrophages in
advanced plaques of 3GA-ctrl mice were decreased compared
with baseline mice, which was likely an effect of plasma lipid
lowering by diet switch, and additional treatment with 3GA-494
even further reduced intra-plaque macrophage numbers. Circu-
lating inflammatory monocytes (Ly6Chi) are associated with pro-
moting plaque progression after extravasation into the lesionMolecular Therapand here, both miRNA-494 and miRNA-329
inhibition resulted in a reduction in circu-
lating pro-inflammatory Ly6Chi monocytes,
which may have caused the reduction in pla-
que macrophages. In addition, platelets have
been described to mediate monocyte activa-
tion, recruitment, and extravasation into the
lesion.31 Therefore, the strongly reduced
blood platelet levels in 3GA-494 mice mayalso have contributed to a reduction in macrophage extravasation
into the lesion.
Particularly, 3GA-494 mice showed reduced levels of circulating in-
flammatory cells, including neutrophils, red blood cells, and platelets,
all of which originate from a common early-myeloid progenitor cell.
Decreased expression of miRNA-494 has been reported to drive
chronic myeloid leukemia, a stem-cell-derived malignant disorder
in human.32 We measured whether transcription factors involved
in HSC proliferation and differentiation were targeted by increased
miRNA-494 expression in the spleen. However, expression levels
were not affected, indicating that this was not primary cause of
reduced levels of circulating neutrophils, red blood cells, and platelets
in 3GA-494 mice. Others have also described a role for 14q32
miRNAs, including miRNA-494, in human erythropoiesis and, there-
fore, proper development of erythrocytes in our murine model may
have been targeted by 3GA-494 treatment.33 Exact mechanisms on
how myeloid cells in the circulation are reduced, however, remains
to be determined in future research.
In previous studies, we have shown that multiple miRNAs transcribed
from the 14q32 cluster are involved in different processes of vascular
remodeling.14–17 Inhibition of 14q32 miRNAs miRNA-494, miRNA-
329, miRNA-487b, and miRNA-495 improved neovascularization
and blood flow recovery in a hindlimb ischemia model.15 Neovascu-
larization requires a pro-inflammatory response, whereas an anti-in-
flammatory response is favorable for atherosclerosis. Stimulation of
neovascularization often leads to aggravation of atherosclerosis and
vice versa.34 This effect is often referred to as the Janus phenomenon,y: Nucleic Acids Vol. 18 December 2019 645
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non, 14q32 miRNA inhibition both increases neovascularization and
reduces atherosclerosis and, therefore, plays a unique role in vascular
remodeling.
Strongly increased megakaryocyte content and increased expression
of transcription factors in the spleen of 3GA-494 mice clearly showed
increased commitment toward the megakaryocyte lineage. Since
SOCS6 expression was not affected upon 3GA-494 treatment in either
the spleen or bone marrow cells, this indicates that megakaryocyte
differentiation was not targeted by 3GA-494 treatment. Increased
splenic megakaryocyte differentiation in 3GA-494 mice is, therefore,
likely a compensatory mechanism to prevent severe thrombocyto-
penia. Others have also demonstrated that mice show increased
megakaryocyte differentiation as a response to lower platelet counts.36
The underlying mechanism of platelet exhaustion may be an
increased hepatic clearance. We found increased platelet receptor
expression in the liver. Apoptotic platelets are recognized and cleared
by the liver.37 However, pro-survival genes Mcl-1 and Bcl-2 were not
clearly affected by miRNA-494 expression in the platelets and were
therefore unlikely the key contributors to increased platelet clearance.
Activation of the platelet receptor GPIb-IX can also lead to rapid he-
patic clearance, and differential expression of the 14q32 cluster has
previously been linked to platelet reactivity.37–39 Indeed, we found
that upregulation of miRNA-494 expression following 3GA-494
treatment led to hyper-activation of platelets. Also, as miRNA-494
expression in the liver itself was not affected by 3GA-494, it is most
likely that increased platelet clearance is caused by platelet activation
in response to 3GA-494 treatment, rather than by upregulation of
clearance pathways in the liver.
A surprising observation in this study is the fact that in both platelets
and in the spleen, 3GA-494 treatment resulted in short-termmiRNA-
494 inhibition followed by a clear miRNA-494 upregulation. The up-
regulation was accompanied by rapid depletion of miRNA-494
precursors in platelets. RNA binding proteins, which are regulated
by miRNAs themselves, are able to regulate miRNA processing in a
cell-specific manner. In a previous study, we have demonstrated
post-transcriptional regulation of miRNA-494 by Mef2A, which
directly binds to pri-miRNA-494.17 However, which precise mecha-
nism underlies the cell- and tissue-specific autoregulation of
miRNA-494 in LDLr/ mice remains to be determined.
Since each cell type has its own specific miRNA and target gene
expression pattern, single miRNA inhibition has distinct effects in
each cell type.29,40,41 Above, we have discussed the effects of
miRNA-494 and miRNA-329 inhibition on SMCs and myofibro-
blasts, on macrophages, and on megakaryocyte cells and platelets,
but also the endothelial cell is of importance in atherosclerosis devel-
opment and progression.We have shown in the past that inhibition of
miRNA-494 had little effect on proliferation of human arterial endo-
thelial cells. Inhibition of miRNA-329, however, increased prolifera-
tion of endothelial cells.15 Whether inhibition of miRNA-329 affects646 Molecular Therapy: Nucleic Acids Vol. 18 December 2019plaque size and composition via increased proliferation of endothelial
cells remains for future research.
In our study, we used a scrambled 3GA as control, and in a previous
study we have established that this 3GA-ctrl does not show significant
differences as compared to vehicle controls.15 Non-specific effects of
this 3GA-ctrl in this study are thus highly unlikely; however, they
cannot be completely excluded. In addition, in this study, we used
LDLr/, which is a strain that allows plasma lipid lowering in
response to a diet switch. Previously, we have shown therapeutic ef-
fects of 3GA-494 in an ApoE/ mouse model, in which atheroscle-
rosis develops in response to elevated lipid levels, which cannot be
lowered using a diet switch. The data from these two studies may
thus not be directly comparable due to strain differences; however,
in both models, 3GA-494 treatment improved lesion size and stabil-
ity. Themost important strength of this study is that we used amurine
model with fully established lesions and started 3GA treatment after
advanced plaques had been formed, while most studies focus on
initial lesion development. Additionally, we included a lipid-lowering
strategy by changing the diet from high-fat high-cholesterol to regular
chow. Since most patients present in the clinic with advanced and un-
stable atherosclerosis and receive routine lipid-lowering treatment,
we more closely mimicked the clinical situation in this study.
Conclusions
In conclusion, inhibition of 14q32 miRNAs, and particularly of
miRNA-494, halts plaque progression and increases plaque stability
in mice with established advanced atherosclerotic lesions. Plasma
cholesterol levels were lowered further by 14q32 miRNA inhibition
than by diet switch alone. Furthermore, pro-atherogenic cells,
including inflammatory Ly6Chi monocytes, neutrophils, and platelets,
were reduced in the circulation. Inhibition of miRNA-494 would
therefore be a potential therapeutic target for stabilizing vulnerable
lesions in patients and may even prevent surgical interventions in
some cases.
MATERIALS AND METHODS
Mice and Experimental Design
All animal work performed conforms to the guidelines from the
Dutch government and the Directive 2010/63/EU of the European
Parliament, and all experiments were approved by the local animal
ethics committee (DEC number 14103). Male LDLr/ mice, aged
8 to 9 weeks, were obtained from our in-house breeding facility (Gor-
laeus Laboratories, Leiden University, Leiden, the Netherlands). Food
and water were available ad libitum.
The timeline of the study is shown in Figure S1. All mice were fed
a Western-type diet (WTD) containing 0.25% cholesterol and 15%
cacao butter (SDS, Sussex, UK) for 10 weeks to induce advanced
atherosclerotic lesions, as described previously.42 Four weeks after
start of the WTD, mice underwent surgical interventions in order
to induce carotid artery plaque formation. As described previously,
semi-constrictive collars were placed around both carotid arteries.14
Mice were anaesthetized by subcutaneous injection of ketamine
www.moleculartherapy.org(60 mg/kg; Eurovet Animal Health, Bladel, the Netherlands), fentanyl
citrate, and fluanisone (1.26 mg/kg and 2 mg/kg, respectively; Janssen
Animal Health, Sauderton, UK).
Six weeks after collar placement, mice were age-, cholesterol-, and
weight-matched to ensure an equal distribution over all groups
before start of the treatment. At that time point, a subset of mice
(n = 10) was sacrificed as baseline control. The remaining mice
were placed on a regular chow diet to lower plasma cholesterol levels,
and 3GAs against miRNA-494 (3GA-494; n = 10), miRNA-329
(3GA-329; n = 10), or negative control (3GA-ctrl; n = 10) was
administered via the tail vein (intravenously [i.v.]) at a concentration
of 1 mg/mouse. 3GAs were designed with perfect reverse comple-
mentary to the mature target miRNA sequence and synthesized by
Idera Pharmaceuticals (Cambridge, MA, USA). The same sequences
of 3GAs (formerly named gene-silencing oligonucleotides [GSOs])
against miRNA-494 and miRNA-329 were used as described previ-
ously.15 As a negative control, a scrambled sequence was used, de-
signed not to target any known murine miRNA. Sequences of the
miRNAs and 3GAs are shown in Table S1. Second and third injec-
tions were given 2 and 4 weeks after diet switch. During the exper-
iment, total serum cholesterol levels were quantified by enzymatic
procedures using Precipath (Roche Diagnostics, Mannheim, Ger-
many). One week after the final 3GA injection, mice were anaesthe-
tized by a subcutaneous injection of a cocktail containing ketamine
(40 mg/mL), atropine (50 mg/mL), and sedazine (6.25 mg/mL). Mice
were subsequently perfused with PBS through the left cardiac
ventricle, after which carotid arteries and other organs were
collected, frozen, and used for further analysis. At sacrifice, whole
blood was analyzed on a Sysmex XT-2000i analyzer (Goffin Meyvis,
Etten Leur, the Netherlands).
Flow Cytometric Analysis
At sacrifice, blood, spleen, and the mediastinal lymph nodes near the
heart (HLN) were isolated. Single-cell suspensions of spleen and HLN
were obtained by squeezing the organs through a 70-mm cell strainer.
Red blood cells were removed using Ammonium-Chloride-Potas-
sium (ACK) lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM
EDTA [pH 7.3]). Immune cells were analyzed with flow cytometry:
T cells (CD4+, CD8+), B cells (CD19+), neutrophils (CD11b+Ly6G+),
and inflammatory monocytes (CD11b+Ly6G-Ly6Chigh). FACS anal-
ysis was performed on a FACSCantoII (BD Biosciences), and data
was analyzed with FlowJo software (Treestar).
RNA Isolation and qRT-PCR
Frozen tissues were crushed by use of pestle and mortar while
immersed in liquid nitrogen. After homogenizing and complete
evaporation of the liquid nitrogen, TRIzol (Thermo Fisher, Bleis-
wijk, the Netherlands) was added to the samples. For carotid artery
RNA isolation, carotid artery segments from three to four mice were
pooled and homogenized with a pellet crusher in TRIzol. Total RNA
was isolated by standard TRIzol-chloroform extraction. RNA con-
centration and purity were measured on the Nanodrop (Nanodrop
Technologies).For miRNAs, miRNA-specific Taqman qPCR kits (Thermo Fisher,
Bleiswijk, the Netherlands) were used for reversed transcription
and quantification by qPCR according to the manufacturers
protocol. For mRNA, RNA was reverse transcribed using a “high-ca-
pacity RNA to cDNA” kit (Thermo Fisher, Bleiswijk, the
Netherlands). SybrGreen reagents (QIAGEN Benelux, Venlo, the
Netherlands) were used for the qPCR. The data were normalized us-
ing a stably expressed endogenous control. miRNA-191 was used for
miRNAs and Gapdh and Hprt for mRNA. qPCR was performed on
the VIIa7 (Applied Biosystems).
Immunohistochemistry
Frozen sections of carotid arteries (10 mm thick) were fixed with
Formal-Fixx (Thermo Fisher, Bleiswijk, the Netherlands) for
30 min and subsequently stained with H&E to determine plaque
size. Analysis was performed on sections throughout the atheroscle-
rotic lesion (100 mm apart, resulting in the average plaque size value)
and at the site of maximal stenosis, the site/section of the plaque that
has the largest plaque size, using Leica Qwin software, as described
previously.43 Mice with plaques containing a reorganized thrombus
were excluded from the plaque size analysis (three mice in baseline,
four mice in 3GA-ctrl, one mouse in 3GA-494, and one mouse in
3GA-329).
To determine lesion size in the three-valve area, cryosections
(10 mm thick) of the aortic root were stained with oil red O and
hematoxylin (Sigma-Aldrich, Zwijndrecht, the Netherlands).
Lesion size was calculated from at least five 10-mm-thick sections
of the three-valve area. Masson’s trichrome staining was used to
visualize collagen and determine necrotic core area. Plaque macro-
phages were stained using a MOMA-2 antibody at a 1:1,000 con-
centration (rat IgG2b, Serotec, Kidlington, UK). SMCs were
stained with a-smooth muscle actin antibody (Clone 1A4,
1:1,000, Abcam, Cambridge, UK). Neutrophils were stained using
the Naphthol AS-D chloroacetate kit (Sigma-Aldrich, Zwijndrecht,
the Netherlands). Collagen, necrotic core size, SMCs, macrophages,
and neutrophils were defined as percentage of total plaque area us-
ing Leica Qwin software.
Frozen cross-sections of spleen and liver were prepared (6 mm thick-
ness) and fixed in ice-cold acetone. An antibody against VWF
(A0082, 1:1000, Dako, Santa Clara, CA, USA) was used to visualize
megakaryocytes in the spleen. Megakaryocytes were counted manu-
ally. ImageJ software was used for area measurements.
Bone Marrow Cells
To isolate bone marrow (BM) cells, femurs and tibias of C57BL/6
mice were dissected, and the bone marrow was flushed with PBS.
BM cells were filtered through a 70-mm cell strainer, centrifuged
at 300  g for 15 min, and suspended in RPMI 1640 medium con-
taining L-glutamine supplemented with 10% heat-inactivated fetal
calf serum (FCSi) and 1% penicillin/streptomycin (P/S). BM cells
were plated at a concentration of 1.8  106 cells/mL and stimulated
with 3GA-494 or 3GA-ctrl at a concentration of 10 ng/mL for 48 hMolecular Therapy: Nucleic Acids Vol. 18 December 2019 647
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were washed with PBS and resuspended in TRIzol for subsequent
RNA isolations.
Human Platelets
Platelets, pooled from five different healthy donors with blood type O
and Rh positive, were obtained from a blood bank facility (Sanquin,
Amsterdam, the Netherlands). The same conditions as used for stor-
age in platelet transfusion were used in the experiment. Platelets in
PAS-III buffer with 30%–35% plasma were transferred from the
transfusion bag into 6-well plates and kept in an incubator at 22C
with 5% CO2 at continuously swirling. Platelet concentration was
0.9–1.3  109/mL and contained < 1  106 leukocytes. Platelets
were untreated, or 3GA-494 or 3GA-ctrl was added at a concentration
of 10 ng/mL and incubated for up to 48 h. As a quality control, pH was
measured at each time point, and platelet parameters were measured
by Sysmex. To pellet the platelets after treatments, platelets were
centrifuged at 800  g for 15 min at room temperature and subse-
quently resuspended in TRIzol.
Statistical Analyses
Results are expressed as mean ± SEM. A Kolmogorov-Smirnov test
was performed to check normal distribution of values. When values
were normally distributed, a two-tailed Student’s t test was used to
compare single-treatment group with the control group.When values
were not normally distributed, a Mann-Whitney U test was per-
formed to compare single treatment with the control group. p <
0.05 was considered significant. A Grubbs’ test was used to identify
significant outliers (a < 0.05).
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.
1016/j.omtn.2019.09.021.
AUTHOR CONTRIBUTIONS
E.v.I., A.C.F., I.B., and A.Y.N. designed the experiments; E.v.I., A.C.F.,
M.J.K, I.B., and A.Y.N. conducted the experiments; E.v.I., A.C.F., I.B.,
A.Y.N., J.K., and P.H.A.Q. wrote, reviewed, and edited the paper; I.B.
and A.Y.N. acquired funding; I.B., A.Y.N., and P.H.A.Q. supervised.
CONFLICTS OF INTEREST
The authors declare no competing interests.
ACKNOWLEDGMENTS
This study was supported by a grant from the Rembrandt Institute of
Cardiovascular Science (2016), the Dutch Heart Foundation (grant
number 2018T051), the CVON GENIUS II program, the LUMC Jo-
hanna Zaaijer Fund (2017), and the Austrian Science Fund FWF (Lise
Meitner Grant, grant number M2578-B30). We acknowledge S.
Agrawal, B. Boersma, and G. Beerends for their technical support.
REFERENCES
1. Libby, P., Ridker, P.M., and Hansson, G.K. (2011). Progress and challenges in trans-
lating the biology of atherosclerosis. Nature 473, 317–325.648 Molecular Therapy: Nucleic Acids Vol. 18 December 20192. Bonati, L.H., Dobson, J., Featherstone, R.L., Ederle, J., van der Worp, H.B., de Borst,
G.J., Mali, W.P., Beard, J.D., Cleveland, T., Engelter, S.T., et al.; International Carotid
Stenting Study investigators (2015). Long-term outcomes after stenting versus endar-
terectomy for treatment of symptomatic carotid stenosis: the International Carotid
Stenting Study (ICSS) randomised trial. Lancet 385, 529–538.
3. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel,
R.H., Goldberg, A.C., Gordon, D., Levy, D., Lloyd-Jones, D.M., et al.; American
College of Cardiology/American Heart Association Task Force on Practice
Guidelines (2014). 2013 ACC/AHA guideline on the treatment of blood cholesterol
to reduce atherosclerotic cardiovascular risk in adults: a report of the American
College of Cardiology/American Heart Association Task Force on Practice
Guidelines. Circulation 129 (Suppl 2 ), S1–S45.
4. Steen, D.L., Khan, I., Ansell, D., Sanchez, R.J., and Ray, K.K. (2017). Retrospective ex-
amination of lipid-lowering treatment patterns in a real-world high-risk cohort in the
UK in 2014: comparison with the National Institute for Health and Care Excellence
(NICE) 2014 lipid modification guidelines. BMJ Open 7, e013255.
5. Crisby, M., Nordin-Fredriksson, G., Shah, P.K., Yano, J., Zhu, J., and Nilsson, J.
(2001). Pravastatin treatment increases collagen content and decreases lipid content,
inflammation, metalloproteinases, and cell death in human carotid plaques: implica-
tions for plaque stabilization. Circulation 103, 926–933.
6. Ridker, P.M., Everett, B.M., Thuren, T., MacFadyen, J.G., Chang, W.H., Ballantyne,
C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S.D., et al.; CANTOS Trial Group
(2017). Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
N. Engl. J. Med. 377, 1119–1131.
7. Welten, S.M., Goossens, E.A., Quax, P.H., and Nossent, A.Y. (2016). The multifacto-
rial nature of microRNAs in vascular remodelling. Cardiovasc. Res. 110, 6–22.
8. Najafi-Shoushtari, S.H., Kristo, F., Li, Y., Shioda, T., Cohen, D.E., Gerszten, R.E., and
Näär, A.M. (2010). MicroRNA-33 and the SREBP host genes cooperate to control
cholesterol homeostasis. Science 328, 1566–1569.
9. Rayner, K.J., Sheedy, F.J., Esau, C.C., Hussain, F.N., Temel, R.E., Parathath, S., van
Gils, J.M., Rayner, A.J., Chang, A.N., Suarez, Y., et al. (2011). Antagonism of
miR-33 in mice promotes reverse cholesterol transport and regression of atheroscle-
rosis. J. Clin. Invest. 121, 2921–2931.
10. Rayner, K.J., Suárez, Y., Dávalos, A., Parathath, S., Fitzgerald, M.L., Tamehiro, N.,
Fisher, E.A., Moore, K.J., and Fernández-Hernando, C. (2010). MiR-33 contributes
to the regulation of cholesterol homeostasis. Science 328, 1570–1573.
11. Price, N.L., Rotllan, N., Canfrán-Duque, A., Zhang, X., Pati, P., Arias, N., Moen, J.,
Mayr, M., Ford, D.A., Baldán, Á., et al. (2017). Genetic Dissection of the Impact of
miR-33a and miR-33b during the Progression of Atherosclerosis. Cell Rep. 21,
1317–1330.
12. Nazari-Jahantigh, M.,Wei, Y., Noels, H., Akhtar, S., Zhou, Z., Koenen, R.R., Heyll, K.,
Gremse, F., Kiessling, F., Grommes, J., et al. (2012). MicroRNA-155 promotes athero-
sclerosis by repressing Bcl6 in macrophages. J. Clin. Invest. 122, 4190–4202.
13. Eken, S.M., Jin, H., Chernogubova, E., Li, Y., Simon, N., Sun, C., Korzunowicz, G.,
Busch, A., Bäcklund, A., Österholm, C., et al. (2017). MicroRNA-210 Enhances
Fibrous Cap Stability in Advanced Atherosclerotic Lesions. Circ. Res. 120, 633–644.
14. Wezel, A.,Welten, S.M., Razawy,W., Lagraauw, H.M., de Vries, M.R., Goossens, E.A.,
Boonstra, M.C., Hamming, J.F., Kandimalla, E.R., Kuiper, J., et al. (2015). Inhibition
of MicroRNA-494 Reduces Carotid Artery Atherosclerotic Lesion Development and
Increases Plaque Stability. Ann. Surg. 262, 841–847, discussion 847–848.
15. Welten, S.M., Bastiaansen, A.J., de Jong, R.C., de Vries, M.R., Peters, E.A., Boonstra,
M.C., Sheikh, S.P., La Monica, N., Kandimalla, E.R., Quax, P.H., and Nossent, A.Y.
(2014). Inhibition of 14q32 MicroRNAs miR-329, miR-487b, miR-494, and miR-
495 increases neovascularization and blood flow recovery after ischemia. Circ. Res.
115, 696–708.
16. Welten, S.M.J., de Jong, R.C.M., Wezel, A., de Vries, M.R., Boonstra, M.C., Parma, L.,
Jukema, J.W., van der Sluis, T.C., Arens, R., Bot, I., et al. (2017). Inhibition of 14q32
microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma
cholesterol levels in experimental restenosis. Atherosclerosis 261, 26–36.
17. Welten, S.M.J., de Vries, M.R., Peters, E.A.B., Agrawal, S., Quax, P.H.A., and Nossent,
A.Y. (2017). Inhibition of Mef2a Enhances Neovascularization via Post-transcrip-
tional Regulation of 14q32 MicroRNAs miR-329 and miR-494. Mol. Ther. Nucleic
Acids 7, 61–70.
www.moleculartherapy.org18. Foks, A.C., van Puijvelde, G.H., Bot, I., ter Borg, M.N., Habets, K.L., Johnson, J.L.,
Yagita, H., van Berkel, T.J., and Kuiper, J. (2013). Interruption of the OX40-OX40
ligand pathway in LDL receptor-deficient mice causes regression of atherosclerosis.
J. Immunol 191, 4573–4580.
19. Fuhrken, P.G., Chen, C., Apostolidis, P.A., Wang, M., Miller, W.M., and Papoutsakis,
E.T. (2008). Gene Ontology-driven transcriptional analysis of CD34+ cell-initiated
megakaryocytic cultures identifies new transcriptional regulators of megakaryopoie-
sis. Physiol. Genomics 33, 159–169.
20. Magnusson, M., Brun, A.C., Miyake, N., Larsson, J., Ehinger, M., Bjornsson, J.M.,
Wutz, A., Sigvardsson, M., and Karlsson, S. (2007). HOXA10 is a critical regulator
for hematopoietic stem cells and erythroid/megakaryocyte development. Blood
109, 3687–3696.
21. Tanabe, O., Shen, Y., Liu, Q., Campbell, A.D., Kuroha, T., Yamamoto, M., and Engel,
J.D. (2007). The TR2 and TR4 orphan nuclear receptors repress Gata1 transcription.
Genes Dev. 21, 2832–2844.
22. Chen, Z., Yi, W., Morita, Y., Wang, H., Cong, Y., Liu, J.P., Xiao, Z., Rudolph, K.L.,
Cheng, T., and Ju, Z. (2015). Wip1 deficiency impairs haematopoietic stem cell func-
tion via p53 and mTORC1 pathways. Nat. Commun. 6, 6808.
23. Nemeth, M.J., Kirby, M.R., and Bodine, D.M. (2006). Hmgb3 regulates the balance
between hematopoietic stem cell self-renewal and differentiation. Proc. Natl. Acad.
Sci. USA 103, 13783–13788.
24. Rontauroli, S., Norfo, R., Pennucci, V., Zini, R., Ruberti, S., Bianchi, E., Salati, S.,
Prudente, Z., Rossi, C., Rosti, V., et al. (2017). miR-494-3p overexpression promotes
megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells
by targeting SOCS6. Oncotarget 8, 21380–21397.
25. Sørensen, A.L., Rumjantseva, V., Nayeb-Hashemi, S., Clausen, H., Hartwig, J.H.,
Wandall, H.H., and Hoffmeister, K.M. (2009). Role of sialic acid for platelet life
span: exposure of beta-galactose results in the rapid clearance of platelets from the
circulation by asialoglycoprotein receptor-expressing liver macrophages and hepato-
cytes. Blood 114, 1645–1654.
26. Mossberg, K., Svensson, P.A., Gidlöf, O., Erlinge, D., Jern, S., and Brogren, H. (2016).
Normalization of qPCR in platelets - YWHAE a potential genericreference gene.
Platelets 27, 729–734.
27. Denis, M.M., Tolley, N.D., Bunting, M., Schwertz, H., Jiang, H., Lindemann, S., Yost,
C.C., Rubner, F.J., Albertine, K.H., Swoboda, K.J., et al. (2005). Escaping the nuclear
confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 122,
379–391.
28. Nassa, G., Giurato, G., Cimmino, G., Rizzo, F., Ravo, M., Salvati, A., Nyman, T.A.,
Zhu, Y., Vesterlund, M., Lehtiö, J., et al. (2018). Splicing of platelet resident pre-
mRNAs upon activation by physiological stimuli results in functionally relevant pro-
teome modifications. Sci. Rep. 8, 498.
29. Goossens, E.A.C., de Vries, M.R., Simons, K.H., Putter, H., Quax, P.H.A., and
Nossent, A.Y. (2019). miRMap: Profiling 14q32 microRNA Expression and DNA
Methylation Throughout the Human Vasculature. Front. Cardiovasc. Med 6, 113.
30. Feig, J.E., Parathath, S., Rong, J.X., Mick, S.L., Vengrenyuk, Y., Grauer, L., Young,
S.G., and Fisher, E.A. (2011). Reversal of hyperlipidemia with a genetic switch favor-ably affects the content and inflammatory state of macrophages in atherosclerotic pla-
ques. Circulation 123, 989–998.
31. Badrnya, S., Schrottmaier, W.C., Kral, J.B., Yaiw, K.C., Volf, I., Schabbauer, G.,
Söderberg-Nauclér, C., and Assinger, A. (2014). Platelets mediate oxidized low-den-
sity lipoprotein-induced monocyte extravasation and foam cell formation.
Arterioscler. Thromb. Vasc. Biol. 34, 571–580.
32. Salati, S., Salvestrini, V., Carretta, C., Genovese, E., Rontauroli, S., Zini, R., Rossi, C.,
Ruberti, S., Bianchi, E., Barbieri, G., et al. (2017). Deregulated expression of miR-29a-
3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in
CML leukemic stem cells. Oncotarget 8, 49451–49469.
33. Lessard, S., Beaudoin, M., Orkin, S.H., Bauer, D.E., and Lettre, G. (2018). 14q32 and
let-7 microRNAs regulate transcriptional networks in fetal and adult human erythro-
blasts. Hum. Mol. Genet. 27, 1411–1420.
34. Parma, L., Baganha, F., Quax, P.H.A., and de Vries, M.R. (2017). Plaque angiogenesis
and intraplaque hemorrhage in atherosclerosis. Eur. J. Pharmacol. 816, 107–115.
35. Epstein, S.E., Stabile, E., Kinnaird, T., Lee, C.W., Clavijo, L., and Burnett, M.S. (2004).
Janus phenomenon: the interrelated tradeoffs inherent in therapies designed
to enhance collateral formation and those designed to inhibit atherogenesis.
Circulation 109, 2826–2831.
36. Barwari, T., Eminaga, S., Mayr, U., Lu, R., Armstrong, P.C., Chan, M.V., Sahraei, M.,
Fernández-Fuertes, M., Moreau, T., Barallobre-Barreiro, J., et al. (2018). Inhibition of
profibrotic microRNA-21 affects platelets and their releasate. JCI Insight 3, 123335.
37. Quach, M.E., Chen, W., and Li, R. (2018). Mechanisms of platelet clearance and
translation to improve platelet storage. Blood 131, 1512–1521.
38. Deng, W., Xu, Y., Chen, W., Paul, D.S., Syed, A.K., Dragovich, M.A., Liang, X., Zakas,
P., Berndt, M.C., Di Paola, J., et al. (2016). Platelet clearance via shear-induced un-
folding of a membrane mechanoreceptor. Nat. Commun. 7, 12863.
39. Edelstein, L.C., Simon, L.M., Montoya, R.T., Holinstat, M., Chen, E.S., Bergeron, A.,
Kong, X., Nagalla, S., Mohandas, N., Cohen, D.E., et al. (2013). Racial differences in
human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat. Med.
19, 1609–1616.
40. Santulli, G. (2015). microRNAs Distinctively Regulate Vascular Smooth Muscle and
Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-
Stent Restenosis. Adv. Exp. Med. Biol. 887, 53–77.
41. Rogg, E.M., Abplanalp, W.T., Bischof, C., John, D., Schulz, M.H., Krishnan, J.,
Fischer, A., Poluzzi, C., Schaefer, L., Bonauer, A., et al. (2018). Analysis of Cell
Type-Specific Effects of MicroRNA-92a Provides Novel Insights Into Target
Regulation and Mechanism of Action. Circulation 138, 2545–2558.
42. van Duijn, J., Kritikou, E., Benne, N., van der Heijden, T., van Puijvelde, G.H., Kröner,
M.J., Schaftenaar, F.H., Foks, A.C., Wezel, A., Smeets, H., et al. (2019). CD8+ T-cells
contribute to lesion stabilization in advanced atherosclerosis by limiting macrophage
content and CD4+ T-cell responses. Cardiovasc. Res. 115, 729–738.
43. Bot, I., Ortiz Zacarías, N.V., de Witte, W.E., de Vries, H., van Santbrink, P.J., van der
Velden, D., Kröner, M.J., van der Berg, D.J., Stamos, D., de Lange, E.C., et al. (2017). A
novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving
high receptor occupancy. Sci. Rep. 7, 52.Molecular Therapy: Nucleic Acids Vol. 18 December 2019 649
